Motif Bio has put together a financing package to give it the money to wrap up a Phase III trial of its antibiotic iclaprim.

New York-based biotech Syntimmune has gained biopharma and VC veteran David de Graaf as its new president and CEO as the company gains the final $8 million…

In its Series A announced today Glycomine, an early-stage biotech working on replacement therapies for rare diseases, raised $12 million with help from…

An entrepreneur who made his fortune building a $14 billion tech company is setting up a life science venture capital fund.

Evotec and the University of Oxford have teamed up to bridge the gap between academic research and industry.

An audible sigh of relief was heard this morning that, at last, the U.S. 2016 election is over. In the end, in what was an oft-controversial, hot-tempered and…

CureVac has raised another $29.5 million to fund the advance of its mRNA pipeline, bringing its total haul up to $360 million.

A clutch of leading U.K. life sciences investors is pooling its resources to create a group with £1 billion ($1.2 billion) in assets.

Venture Capital